Table 1.
Risk factor | Impact on PML risk |
---|---|
Longer duration of natalizumab treatment | Incidence of PML according to duration of natalizumab exposure:
|
Prior immunosuppressant treatment | Immunosuppressants associated with PML include mitoxantrone, cyclophosphamide, methotrexate, azathioprine, and mycophenolate. |
Presence of anti-JCV antibodies | Estimated incidence of PML according to anti-JCV antibody status:
|
CI=confidence interval; JCV=JC virus.
Data from Sørensen PS, et al.6